Market Overview

Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report


Deutsche Bank maintained its Buy rating on Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) despite the company's second quarter earnings miss.

"While management's mention of a slowdown in the diagnosis of narcolepsy and continued payer hurdles may create some concern that Xyrem growth will slow, we were encouraged by the strong performance of Defitelio, and look forward to the approval and launch of Vyxeos in 2017," analyst Gregg Gilbert wrote in a note.

The analyst noted that the continued growth of Defitelio and Vyxeos will be key going forward, and expects the management to remain active on the business development front.

Gilbert also lowered his Xyrem estimates based on more conservative volume growth in 2017-20 (4 percent versus prior 5-6 percent), while raising Defitelio estimates. These changes reduced his total revenue estimates by about 2-4 percent.

Consequently, Gilbert's 2016 EPS estimate fell to $8.74 (from $9.91) and 2017 EPS view to $10.60 (from $13.15). Excluding stock compensation expense, the analyst's 2016 EPS would be $10.02 (versus the company's target of $9.90 - $10.30).

However, the analyst raised his price target by $3 to $158.

"We acknowledge that our PT does not imply very significant upside, but more upside is possible if JAZZ can create certainty around Xyrem's duration (by settling with first-filer Hikma/Roxane or winning in court) and/or with smart business development," Gilbert added.

At time of writing, shares of Jazz fell 1.17 percent to $138.37.

Latest Ratings for JAZZ

Jan 2020Wells FargoMaintainsOverweight
Dec 2019Wells FargoMaintainsOutperform
Dec 2019BarclaysMaintainsOverweight

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Gregg GilbertAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (JAZZ)

View Comments and Join the Discussion!

Latest Ratings

GRPNMorgan StanleyMaintains1.5
HMSYCantor FitzgeraldReiterates33.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at